BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in
treating patients with recurrent or metastatic solid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC